All issues
Volume 49, Issue 7
Displaying 1-5 of 5 articles from this issue
- |<
- <
- 1
- >
- >|
-
II Sensitivities to Commonly Used Antibiotics, Some of Anti-Neoplastic Agents, an Anti-Leprotic and an Antifungus AgentFumiyuki KUZE, Sadao TAKEDA, Nobuo MAEKAWA1974 Volume 49 Issue 7 Pages 189-194
Published: July 15, 1974
Released on J-STAGE: May 24, 2011
JOURNAL FREE ACCESSThe sensitivity of the atypical mycobacterial strains to various drugs other than antituber'culous drugs was studied in vitro using Dubos Tween Albumin liquid medium. The atypical mycobacterial strains tested were chosen from 53 strains including 7 photochromogens (M. kansasii), 8 scotochromogens, 30 nonphotochromogens (M. intracellulare) and 8 rapid growers.
Among the commonly used antibiotics the following was studied; Potassium Benzylp e nicillin (PC-G), Sodium Ampicillin (AB-PC), Sodium Cloxacillin (MCI-PC), Kitasamycin (LM), Cephaloridine (CER), Aminodeoxykanamycin (AKM), Demethylchlortetracycline (DMCT), Paromomycin (PRM) as well as two anti-neoplastic agents, Bleomycin (BLM) and Mitomycin C. A phenazine derivative Riminophenazine B 663, which is being investigated as an anti-leprotic agent, and an antifungus agent BAY b 5097 were also studied.
When the growth of mycobacteria was inhibited at t he concentrations of O.78 m cg/ml or less of any drug, the drug was defined as tentatively sensitive, and under this condition over fifty per cent of the nonphotochromogens (M. intracellulare) were sensitive to DMCT (63%)and PRM (53%). (The numbers in the parentheses are the percentages of the sensitive stra ins.)The Minimal Inhibitory Concentrations of BLM and Mitomycin C were O.78 mcg/ml or less in 37% and 48% of the nonphotochromogens, respectively. B 663 showed fairly constant in vitro effect to the atypical mycobacteria tested, and 75% of the nonphotochromogens were inhibited -their growth at the concentrations of O.156 m cg/ml to 0.625 m cg/ml. Photochromogen s seemed to be most sensitive to B 663 and the rapid growers were less sensitive than the other strains. All the strains tested were resistant to BAY b 5097.View full abstractDownload PDF (1081K) -
Masahiko YAMAMOTO, Munehiko MORISHITA, Yoshinori HIRANO, Akira NAGATA, ...1974 Volume 49 Issue 7 Pages 195-199
Published: July 15, 1974
Released on J-STAGE: May 24, 2011
JOURNAL FREE ACCESSThe course of the sputum examination were followed up for 24 months in 94 cases of previonsly treated advanced pulmonary tuberculosis whose sputum coverted to negative consecutively at the 4th, 5th and 6th months after the adminstration of Rifampicin (RFP).View full abstractDownload PDF (869K) -
Tuberculosis Research Committee, RYOKEN1974 Volume 49 Issue 7 Pages 201-206
Published: July 15, 1974
Released on J-STAGE: May 24, 2011
JOURNAL FREE ACCESSThe main purpose of this study was based on determinating whether or not the incidence of disturbance of liver function was influenced by postoperative administration of Rifampicin (RFP) and/or Ethionamide (TH) for pulmonary tuberculosis. The material consisted of 1, 191cases who had undergone the operation at institutions participating to the Tuberculosis Research Committee (Ryiiken) and were followed up for the period of at least 6 months postoperatively.View full abstractDownload PDF (1209K) -
The Research Committee for Tuberculosis, RYOKEN1974 Volume 49 Issue 7 Pages 207-215
Published: July 15, 1974
Released on J-STAGE: May 24, 2011
JOURNAL FREE ACCESSThe efficacy and the side-effects of Tuberactinomycin-N (TUM-N) in the retreatment of pulmonary tuberculosis were studied and compaired with those of Viomycin (VM). The drug resistance of tubercle bacilli isolated from the patients during treatment was also studied for TUM-N and VM.
TUM-N i s a new antituberculous drug isolated from the culture filtrate of Streptomyces. griseoverticillatus var. tuberacticus (N 6-130 strain). This drug shows almost the same activity as VM for tubercle bacilli and one way cross resistance for kanamycin.
In this study, two following regimens were allocated ran d o mly for retreated patients.
(1) TUM-N group: TUM-N was injected 1 g daily for the first three months, thereafter injected twice weekly. (45 cases)
(2) VM group: VM wa s injected 1 g three times a week. (38 cases)
If there are previously unused drug, they were combined with TUM-N or VM. The results were summarized as follows;
(1) TUM-N group showed slmo s t the same negative conversion rate on culture as VM, group.
(2) All of the cases treated with TUM-N combined with two previously unused drugs. showed 100% negative conversion rate on culture at 6 months.
(3) The incidence of side-effects was lower in TU M -N group compared with VM group. The auditory disturbance was 2.2% in TUM-N group and 5.7% in VM group. The renal, disturhance defined by the raise of BUN level over 20 mg/dl was observed in 23.7% among -VM group while it was 10.9% in TUM-N group. The dropped-out cases due to side-effects -were 3 (6.5%) among 46 cases of TUM-N group and 8(21.2%) among 38 cases of VM group.
(4) The criterion of drug resistance of TUM-N was examined and it was concluded that the growth on 1% Ogawa's media containing 100 mcg/ml TUM-N should be considered as resistant.View full abstractDownload PDF (1776K) -
Masatoyo AKIYOSHI, Munetoshi YOSHIZAWA, Kazuo HAYANO1974 Volume 49 Issue 7 Pages 217-223
Published: July 15, 1974
Released on J-STAGE: May 24, 2011
JOURNAL FREE ACCESSThe present study was made to evaluate the nephrotoxicity of Tuberactinomycin-N (TUMN), a newly developed peptide antibiotic isolated from the culture broth of the mutant strain of Streptomyces grieseoverticillatus var. tuberacticus and to clarify the interrelation bet ween the nephrotoxicity and ototoxicity.View full abstractDownload PDF (7597K)
- |<
- <
- 1
- >
- >|